相关实验视频

Updated: Jul 10, 2025

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

冠状动脉使用后静脉内石的不良反应:来自FDA MAUDE数据库的报告

Athanasios Rempakos¹, Bahadir Simsek¹, Spyridon Kostantinis¹

¹Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA.

The Journal of invasive cardiology

|November 20, 2023

概括

血管内透症 (IVL) 在严重化的冠状动脉病变中显示了现实世界的结果. 这项研究分析了MAUDE数据库中报告的不良事件,以评估IVL的安全性和有效性.

科学领域:

心血管医学心血管医学
医疗器械技术医疗器械技术
干预心脏病学干预心脏病学

背景情况:

对于严重化的病变,穿皮冠状动脉干预 (PCI) 存在挑战和更高的并发症率.
静脉内 (IVL) 是一种较新的技术,已被批准用于新的结石化冠状动脉病变,但现实数据有限.
了解与IVL相关的不良事件对于临床实践至关重要.

研究的目的:

为了评估静脉内石 (IVL) 在治疗结石化冠状动脉病变中的真实世界的安全性和结果.
对IVL设备的MAUDE数据库中报告的不良事件进行全面分析.
提供IVL在受控临床试验之外的表现的见解.

主要方法:

从2021年2月12日到2023年2月28日,对MAUDE数据库进行了全面搜索.
关键词"冲击波医学"和"冲击波"被用来识别相关的不良事件报告.
考虑了与IVL导管使用相关的所有潜在不良结果.

主要成果:

该研究确定并分析了与IVL使用相关的不良事件在现实环境中.
马德数据库提供了非识别数据,简化了审查过程.
特定类型和与IVL相关的并发症的频率被目录.

结论:

来自MAUDE数据库的现实世界数据为血管内石的安全概况提供了有价值的见解.
持续监测设备性能对于理解IVL的长期结果至关重要.
这项分析为日益增长的IVL复杂冠状动脉干预的证据提供了贡献.

关键词:

这是PCI的PCI.静脉内静脉体内三.通过皮肤进行冠状动脉干预.

更多相关视频

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

The Intra-Aortic Balloon Pump

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

相关概念视频

Pharmacovigilance

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...

Cardiac Catheterization IV: Nursing Management

Cardiac Catheterization IV: Nursing Management

Nursing responsibilities before cardiac catheterization include:Assess for allergies and establish baseline health status.Before cardiac catheterization, assess the patient for allergies to contrast dye. Perform a comprehensive baseline assessment, including vital signs, heart and breath sounds, and a neurovascular assessment of the extremities, noting distal pulses, skin color, and temperature. Instruct the patient to fast for 8-12 hours before the procedure. Evaluate baseline laboratory...

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Antihypertensive Drugs: Direct Renin Inhibitors

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...